CVRx (NASDAQ:CVRX) Rating Lowered to Sell at Wall Street Zen

CVRx (NASDAQ:CVRX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other analysts have also recently issued reports about the company. Lake Street Capital cut CVRx from a “buy” rating to a “hold” rating and set a $3.50 target price for the company. in a research report on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of CVRx in a research report on Tuesday, April 14th. Piper Sandler cut CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research note on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of CVRx in a report on Monday, August 3rd. Finally, Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $6.90.

CVRx Price Performance

Shares of CVRX opened at $2.39 on Friday. CVRx has a 1-year low of $2.30 and a 1-year high of $11.30. The stock has a market cap of $63.67 million, a PE ratio of -1.21 and a beta of 0.81. The company has a debt-to-equity ratio of 2.94, a current ratio of 8.04 and a quick ratio of 6.87. The firm has a fifty day moving average price of $5.19 and a 200 day moving average price of $6.50.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.01). CVRx had a negative return on equity of 152.35% and a negative net margin of 84.93%.The firm had revenue of $15.71 million for the quarter, compared to analysts’ expectations of $15.55 million. As a group, sell-side analysts anticipate that CVRx will post -1.89 EPS for the current year.

Hedge Funds Weigh In On CVRx

Several institutional investors have recently added to or reduced their stakes in CVRX. Johnson & Johnson purchased a new stake in CVRx during the 2nd quarter valued at approximately $20,687,786,000. BlackRock Inc. acquired a new stake in CVRx during the 2nd quarter worth approximately $6,402,000. GSK plc purchased a new position in shares of CVRx in the 4th quarter valued at approximately $7,154,000. Royal Bank of Canada grew its stake in shares of CVRx by 6,559.3% in the 1st quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock valued at $6,688,000 after purchasing an additional 696,334 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in shares of CVRx by 65.5% in the second quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after purchasing an additional 267,063 shares during the period. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx News Summary

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.